MIA's Peter Simons interviews David Cohen, PhD, on his path to researching mental health, coercive practices, and discontinuation from psychiatric drugs.
Research illustrates privacy concerns with how mental health applications collect and share users’ data.
Akansha Vaswani interviews Dr. John Read about the influences on his work and his research on madness, psychosis, and the mental health industry.
Researchers compare differences between research and clinical diagnoses of ADHD and explore the consistency of clinical determinations over time
Industry-funded continuing medical education (CME) influences physicians to prescribe more opioids, focus less on the consequences.
A new study casts doubt on whether such biotypes for depression exist.
New study finds that antidepressants may negatively impact recovery after psychiatric hospitalization.
Could the statistical phenomenon of regression to the mean be responsible for the dramatic effects of placebo—as well as the supposed effectiveness of some psychiatric drugs?
Researchers examine how rapid discontinuation can mimic the relapse of mental health symptoms and confound psychiatric drug studies.
A new study provides an insider’s look into how psychiatrists view the establishment of drug-free programs in Norway.
Neuroscience researchers find no differences in brain connectivity between children with diagnoses of autism, ADHD, and those with no diagnoses.
Debate ensues as scholars and policymakers discuss how to bring a rights-based approach to mental health policy.
Twice as many teenagers with ADHD experienced severe psychosis when taking Adderall, as compared to Ritalin, according to a new study.
A new study investigated whether participants guessing if they have an antidepressant or placebo affects response rates.
The candidate-gene approach to depression goes unsupported and is likely based on bad science, new research finds.
Dr. Gail Hornstein, author of Agnes’s Jacket: A Psychologist’s Search for the Meanings of Madness, discusses the importance of personal narratives and service-user activism in the context of the global mental health movement.
The latest issue of the journal Behavioral and Brain Sciences features several prominent researchers arguing that mental health concerns are not “brain disorders.”
Researchers examine psychiatrist-client interactions and find that clients are often left with few opportunities to make explicit requests to change their medication regimen.
A new article in Lancet Psychiatry finds that slower tapering of SSRIs is better for preventing antidepressant withdrawal effects.
CBT forwards a hyper-rational perspective of human suffering that complements a managerialist culture of efficiency and institutionalization in the Western world.
My story is not just about the personal costs of speaking truth to power. This is a story about institutional corruption and one of the worst show trials in academia that you can imagine. I have written a book that documents the truth, backed by leaked board room recordings, private emails and testimony from concerned citizens.
“Converging lines of evidence now suggest that depression—a common comorbidity in the setting of chronic pain—may in some patients represent an unrecognized yet potentially reversible harm of opioid therapy.”
Researchers question the overstated results of a large antidepressant meta-analysis and point to cultural pressures to turn to these drugs for a quick fix.
John Ioannidis, a leading expert on research methods, takes a critical look at the way professional societies write treatment guidelines.
Dr. Dainius Pūras argues that the status quo in mental health treatment is no longer acceptable and demands political action to promote human rights.